去甲基烟碱

Nornicotine

	产品编号	CFN80056
	CAS编号	494-97-3
	分子式 = 分子量	C₉H₁₂N₂ = 148.10
	产品纯度	>=98%
	物理属性	Powder
	化合物类型	Alkaloids
	植物来源	The herbs of Nicotiana tabacum.
ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用

提供自定义包装

产品名称	产品编号	CAS编号	包装	QQ客服
去甲基烟碱	CFN80056	494-97-3	1mg	QQ客服：2159513211
去甲基烟碱	CFN80056	494-97-3	5mg	QQ客服：2159513211
去甲基烟碱	CFN80056	494-97-3	10mg	QQ客服：2159513211
去甲基烟碱	CFN80056	494-97-3	20mg	QQ客服：2159513211

存储与注意事项

1. 在您收到产品后请检查产品。如无问题，请将产品存入冰霜并且样品瓶保持密封，产品可以存放长达24个月（2-8摄氏度）。

2. 只要有可能，产品溶解后，您应该在同一天应用于您的实验。但是，如果您需要提前做预实验，或者需要全部溶解，我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。通常，这些可用于长达两周。使用前，打开样品瓶前，我们建议您将产品平衡至室温至少1小时。

3. 需要更多关于溶解度，使用和处理的建议？请发送电子邮件至：service@chemfaces.com

订购流程

1. 在线订购

请联系我们QQ客服

2. 电话订购

请拨打电话：
027-84237683 或 027-84237783

3. 邮件或传真订购

发送电子邮件到: manager@chemfaces.com 或
发送传真到：027-84254680

提供订购信息

为了方便客户的订购，请需要订购ChemFaces产品的客户，在下单的时候请提供下列信息，以供我们快速为您建立发货信息。

1. 产品编号（CAS No.或产品名称）

2. 发货地址

3. 联系方法 (联系人，电话）

4. 开票抬头 (如果需要发票的客户）

5. 发票地址（发货地址与发票地址不同）

发货时间

1. 付款方式为100%预付款客户，我们将在确认收到货款后当天或1-3个工作日发货。

2. 付款方式为月结的客户，我们承诺在收到订单后当天或1-3个工作日内发货。

3. 如果客户所需要的产品，需要重新生产，我们有权告知客户，交货时间需要延期。

Description:

Nornicotine serves as the direct precursor in the synthesis of N'-nitrosonornicotine, a potent carcinogen in laboratory animals. Nornicotine and nicotine can promote endothelial cellular proliferation, migration and tube formation of HUVECs in vitro.Nornicotine and nicotine each produced a dose-dependent decrease in nicotine self-administration, nornicotine may be an effective treatment for tobacco dependence. S(-)-Nornicotine may be of value, either alone or in combination with an opioid, for treatment of a broad-spectrum of pain (i.e. nociceptive, neuropathic, and mixed pain).Nornicotine inhibits striatal dopamine transporter (DAT) function via a nicotinic receptor (nAChR) -mediated mechanism.

Targets:

P450 (e.g. CYP17) | AChR | VEGFR

In vitro:

Ophthalmic Res. 2015;55(1):1-9.

Nornicotine and Nicotine Induced Neovascularization via Increased VEGF/PEDF Ratio.[Pubmed: 26536586]

The purpose of the current study was to evaluate the influences of Nornicotine and nicotine (NT) in cigarette smoke on the expression of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) in retinal pigment epithelium cells and human umbilical vein endothelial cells (HUVECs). Furthermore, the angiogenic behaviors of endothelial cells under Nornicotine and NT treatment were assessed by using in vitro methods.
METHODS AND RESULTS:
ARPE-19 cells and HUVECs were treated with different concentrations of either Nornicotine or NT for different periods of time. The cell proliferative effect was investigated by using the method of MTT analysis. HUVEC migration and tube formation were assessed by using the scratch assay and Matrigel models. The expressions of VEGF and PEDF gene and protein in both types of cells were examined by real-time RT-PCR and Western blot. There was no proliferation of ARPE-19 cells following treatment with various concentrations of Nornicotine or NT. In contrast, Nornicotine or NT significantly stimulated HUVEC proliferation, migration and tube formation. Nornicotine and NT upregulated the expression of VEGF but suppressed the expression of PEDF at both mRNA and protein levels in a dose- and time-dependent manner in ARPE-19 cells and HUVECs.
CONCLUSIONS:
Our results demonstrate that Nornicotine and NT promoted endothelial cellular proliferation, migration and tube formation of HUVECs in vitro. These effects might be partly due to simultaneous modulation of VEGF/PEDF signaling in ARPE-19 cells and HUVECs.

In vivo:

Psychopharmacology (Berl). 2000 Oct;152(3):289-94.

Nornicotine pretreatment decreases intravenous nicotine self-administration in rats.[Pubmed: 11105939]

Nicotine has been shown to be effective as a treatment for reducing tobacco dependence. However, few studies have examined the effect of other nicotinic agonists to determine if they can also decrease nicotine self-administration. The present study determined if Nornicotine, a tobacco alkaloid and major nicotine metabolite in brain, could reduce nicotine self-administration in rats.
METHODS AND RESULTS:
Each rat was prepared with an indwelling jugular catheter and trained to self-administer intravenous nicotine (0.03 mg/kg per infusion). After nicotine self-administration stabilized, rats were pretreated with either (-)-nicotine (0, 0.1, 0.3, and 1.0 mg/kg free base) or (+/-)-Nornicotine (0, 1, 3, 5.6, and 10.0 mg/kg free base) and assessed for nicotine self-administration. A separate group of rats was maintained on sucrose reinforced responding and pretreated with Nornicotine to determine the specificity of the pretreatment effect. In another group of rats, the time course of the pretreatment effect of either (-)-nicotine (0.56 and 1.0 mg/kg) or (+/-)-Nornicotine (5.6 and 10.0 mg/kg) was examined. Nicotine and Nornicotine each produced a dose-dependent decrease in nicotine self-administration. Furthermore, the decrease in nicotine self-administration in response to the 5.6 mg/kg Nornicotine pretreatment was specific to nicotine self-administration, as this dose did not decrease sucrose reinforced responding in tolerant animals. In addition, within the dose range tested, the suppressant effect of Nornicotine had a two-fold longer duration than that of nicotine (120 versus 60 min).
CONCLUSIONS:
These results suggest that Nornicotine may be an effective treatment for tobacco dependence.

Synapse. 2007 Mar;61(3):157-65.

Nornicotine inhibition of dopamine transporter function in striatum via nicotinic receptor activation.[Pubmed: 17146768]

Nornicotine, a tobacco alkaloid and N-demethylated nicotine metabolite, releases DA from superfused rat striatal slices in a mecamylamine-sensitive manner, indicating nicotinic receptor (nAChR) modulation of this response.
METHODS AND RESULTS:
The current study determined the effect of Nornicotine on rat striatal dopamine transporter (DAT) function using in vivo voltammetry. In a dose-related and mecamylamine-sensitive manner, Nornicotine (0.35-12.0 mg/kg, s.c.) decreased DA clearance, suggesting that Nornicotine inhibits striatal DAT function via a nAChR-mediated mechanism. Furthermore, the nAChRs mediating the Nornicotine-induced inhibition of DAT function appear to be different from those activated by nicotine which increases DA clearance.
CONCLUSIONS:
Understanding the actions of Nornicotine in brain may have significance for emerging therapeutics and for the management of nicotine dependence.

产品名称	产品编号	CAS编号	分子式 = 分子量	位单	联系QQ
5-羟基-2-吡咯烷酮; 5-Hydroxy-2-pyrrolidinone	CFN97072	62312-55-4	C₄H₇NO₂ = 101.1	5mg	QQ客服：1413575084
蕨内酰胺; Pterolactam	CFN98614	38072-88-7	C₅H₉NO₂ = 115.1	5mg	QQ客服：3257982914
盐酸水苏碱; Stachydrine hydrochloride	CFN98506	4136-37-2	C₇H₁₄ClNO₂ = 179.64	20mg	QQ客服：2159513211
脯氨酸; Proline	CFN99612	147-85-3	C₅H₉NO₂ = 115.1	20mg	QQ客服：1457312923
去甲基烟碱; Nornicotine	CFN80056	494-97-3	C₉H₁₂N₂ = 148.10	5mg	QQ客服：3257982914
L-尼古丁; L-Nicotine	CFN99512	54-11-5	C₁₀H₁₄N₂ = 162.23	20mg	QQ客服：215959384
(1'S.2'S)-尼古丁1'-氧化物 ; Nicotine 1'-N-oxide	CFN96582	51095-86-4	C₁₀H₁₄N₂O = 178.23	5mg	QQ客服：3257982914
Aglain C; Aglain C	CFN96309	177468-85-8	C₃₆H₄₂N₂O₈ = 630.7	5mg	QQ客服：2159513211
Aglain B; Aglain B	CFN96344	177262-32-7	C₃₆H₄₂N₂O₈ = 630.7	5mg	QQ客服：2159513211
Aglaxiflorin D; Aglaxiflorin D	CFN96299	269739-78-8	C₃₆H₄₂N₂O₉ = 646.7	5mg	QQ客服：2056216494

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	6.7522 mL	33.761 mL	67.5219 mL	135.0439 mL	168.8049 mL
5 mM	1.3504 mL	6.7522 mL	13.5044 mL	27.0088 mL	33.761 mL
10 mM	0.6752 mL	3.3761 mL	6.7522 mL	13.5044 mL	16.8805 mL
50 mM	0.135 mL	0.6752 mL	1.3504 mL	2.7009 mL	3.3761 mL
100 mM	0.0675 mL	0.3376 mL	0.6752 mL	1.3504 mL	1.688 mL

去甲基烟碱

Nornicotine

信息支持

联系方式